Non-Viral Delivery Systems & LNP Platforms for Genetic Therapies Market
完整報告名稱與涵蓋範圍
Non-Viral Delivery Systems & LNP Platforms for Genetic Therapies Market Size, Share & Trends Analysis Report, By Delivery Platform (Lipid Nanoparticles, Polymeric and Peptide Nanocarriers, Exosome and Virus-Like Particle Delivery, Conjugate and Ligand-Targeted Delivery), By Payload (mRNA and Self-Amplifying RNA, siRNA and Antisense Oligonucleotides, Gene Editing Components (CRISPR, Base and Prime Editors), DNA and Other Genetic Payloads), By Target Tissue (Liver, Extrahepatic Tissues (Lung, Muscle, CNS, Immune Cells), Local and Ex Vivo Delivery), By Business Model, By Region, and Segment Forecasts, 2026-2035
報告摘要
The non-viral delivery systems and LNP platforms for genetic therapies market covers the delivery technologies that carry mRNA, self-amplifying RNA, siRNA, antisense oligonucleotides, gene-editing components and DNA into cells without viral vectors, including lipid nanoparticles, polymeric and peptide carriers, exosome and virus-like particle systems and ligand-targeted conjugates, monetised through platform licensing, partnerships, internal pipelines and component supply. The lipid nanoparticle formulation and raw material market for approved vaccines is covered in a separate InsightAce study; this study concentrates on delivery platform value for genetic therapies, including extrahepatic targeting.
The success of mRNA vaccines and liver-directed gene editing validated lipid nanoparticles, and the field is now focused on delivering payloads beyond the liver to lung, muscle, brain, hematopoietic stem cells and immune cells, which would unlock in vivo CAR-T, muscular dystrophy and CNS indications. Ionizable lipid libraries, selective organ targeting, antibody- and peptide-decorated particles and non-lipid carriers compete on tissue tropism, redosability and tolerability, and licensing terms for delivery intellectual property have become a major economic layer in genetic medicine. Litigation over foundational lipid patents, manufacturing scale-up of complex particles and the need for repeat dosing in chronic diseases shape strategy.
North America and Europe dominate platform ownership and partnering, with China emerging as a source of alternative lipid chemistries. Competition includes delivery-focused biotechnology companies, genetic medicine developers with proprietary platforms and lipid and excipient suppliers.
The InsightAce study provides US$ revenue forecasts for every delivery platform, payload, target tissue and business model and regional segment over 2026-2035, plus segment trend analysis, competitive landscape mapping and profiles of leading participants.
授權報價
| Single User | $4,500 USD |
| Enterprise / Global Site Licence | $9,500 USD |
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Non-Viral Delivery Systems & LNP Platforms for Genetic Therapies Market Snapshot
Chapter 4. Global Non-Viral Delivery Systems & LNP Platforms for Genetic Therapies Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Market Drivers
4.3. Market Challenges
4.4. Emerging Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis - Porter's Five Forces Analysis
4.7. Competitive Landscape and Market Positioning
4.8. Market Opportunity Analysis
Chapter 5. Market Segmentation 1: By Delivery Platform Estimates & Trend Analysis
5.1. Delivery Platform & Market Share, 2026 & 2035
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Delivery Platform:
5.2.1. Lipid Nanoparticles
5.2.2. Polymeric and Peptide Nanocarriers
5.2.3. Exosome and Virus-Like Particle Delivery
5.2.4. Conjugate and Ligand-Targeted Delivery
Chapter 6. Market Segmentation 2: By Payload Estimates & Trend Analysis
6.1. Payload & Market Share, 2026 & 2035
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Payload:
6.2.1. mRNA and Self-Amplifying RNA
6.2.2. siRNA and Antisense Oligonucleotides
6.2.3. Gene Editing Components (CRISPR, Base and Prime Editors)
6.2.4. DNA and Other Genetic Payloads
Chapter 7. Market Segmentation 3: By Target Tissue Estimates & Trend Analysis
7.1. Target Tissue & Market Share, 2026 & 2035
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Target Tissue:
7.2.1. Liver
7.2.2. Extrahepatic Tissues (Lung, Muscle, CNS, Immune Cells)
7.2.3. Local and Ex Vivo Delivery
Chapter 8. Market Segmentation 4: By Business Model Estimates & Trend Analysis
8.1. Business Model & Market Share, 2026 & 2035
8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Business Model:
8.2.1. Platform Licensing and Partnerships
8.2.2. Internal Pipeline Development
8.2.3. Delivery Components and Services
Chapter 9. Non-Viral Delivery Systems & LNP Platforms for Genetic Therapies Market: Regional Estimates & Trend Analysis
9.1. North America
9.1.1. United States
9.1.2. Canada
9.2. Europe
9.2.1. Germany
9.2.2. United Kingdom
9.2.3. France
9.2.4. Italy
9.2.5. Spain
9.2.6. Rest of Europe
9.3. Asia Pacific
9.3.1. China
9.3.2. Japan
9.3.3. India
9.3.4. South Korea
9.3.5. Australia
9.3.6. Southeast Asia
9.3.7. Rest of Asia Pacific
9.4. Latin America
9.4.1. Brazil
9.4.2. Mexico
9.4.3. Rest of Latin America
9.5. Middle East & Africa
9.5.1. GCC Countries
9.5.2. South Africa
9.5.3. Rest of Middle East & Africa
Chapter 10. Competitive Landscape
10.1. Company Market Positioning Analysis
10.2. Strategic Developments (Partnerships, Expansions, Product Launches, M&A)
Chapter 11. Company Profiles
11.1. Moderna, Inc.
11.2. Acuitas Therapeutics Inc.
11.3. Genevant Sciences
11.4. Arbutus Biopharma Corporation
11.5. ReCode Therapeutics, Inc.
11.6. Intellia Therapeutics, Inc.
11.7. Beam Therapeutics Inc.
11.8. Sirnaomics Ltd.
11.9. Nanite, Inc.
11.10. Capstan Therapeutics (AbbVie Inc.)
11.11. Generation Bio Co.
11.12. Alnylam Pharmaceuticals, Inc.
11.13. Evonik Industries AG
11.14. Croda International Plc
11.15. Carmine Therapeutics
圖表清單 List of Tables & Figures
Table 1. Global Non-Viral Delivery Systems & LNP Platforms for Genetic Therapies Market Revenue Forecast by Delivery Platform, 2026-2035 (US$ Mn)
Figure 1. Global Non-Viral Delivery Systems & LNP Platforms for Genetic Therapies Market Segmentation and Scope Overview
Table 2. Global Non-Viral Delivery Systems & LNP Platforms for Genetic Therapies Market Revenue Forecast by Payload, 2026-2035 (US$ Mn)
Figure 2. Global Non-Viral Delivery Systems & LNP Platforms for Genetic Therapies Market Share by Delivery Platform, 2026 & 2035
Table 3. Global Non-Viral Delivery Systems & LNP Platforms for Genetic Therapies Market Revenue Forecast by Target Tissue, 2026-2035 (US$ Mn)
Figure 3. Delivery Platform Landscape by Carrier Type, Payload Compatibility and Tissue Tropism
Table 4. Global Non-Viral Delivery Systems & LNP Platforms for Genetic Therapies Market Revenue Forecast by Business Model, 2026-2035 (US$ Mn)
Figure 4. Extrahepatic Delivery Programs by Target Tissue and Clinical Stage, 2026
Table 5. Global Non-Viral Delivery Systems & LNP Platforms for Genetic Therapies Market Revenue Forecast by Region, 2026-2035 (US$ Mn)
Figure 5. Asia Pacific Non-Viral Delivery Systems & LNP Platforms for Genetic Therapies Growth Opportunity Analysis
Table 6. North America Non-Viral Delivery Systems & LNP Platforms for Genetic Therapies Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 6. Competitive Positioning of Key Non-Viral Delivery Systems & LNP Platforms for Genetic Therapies Market Participants
Table 7. Europe Non-Viral Delivery Systems & LNP Platforms for Genetic Therapies Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 7. Porter's Five Forces Analysis of the Global Non-Viral Delivery Systems & LNP Platforms for Genetic Therapies Market
Table 8. Asia Pacific Non-Viral Delivery Systems & LNP Platforms for Genetic Therapies Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 8. Delivery Intellectual Property Licensing Structures and Litigation Landscape
Table 9. Strategic Developments of Leading Non-Viral Delivery Systems & LNP Platforms for Genetic Therapies Market Participants, 2023-2026
提及公司
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們